

# Antonella Castagna

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6385829/antonella-castagna-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

340  
papers

12,840  
citations

50  
h-index

106  
g-index

349  
ext. papers

15,061  
ext. citations

6.1  
avg, IF

5.83  
L-index

#	Paper	IF	Citations
340	Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy.. <i>Drug Design, Development and Therapy</i> , <b>2022</b> , 16, 297-304	4.4	0
339	Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance.. <i>Sexually Transmitted Infections</i> , <b>2022</b> ,	2.8	1
338	Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofac029	1	1
337	Levels of Alpha-Fetoprotein and Association with Mortality in Hepatocellular Carcinoma of HIV-1-Infected Patients.. <i>Journal of Oncology</i> , <b>2022</b> , 2022, 3586064	4.5	1
336	Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0262917	3.7	0
335	Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects.. <i>Pharmacological Research</i> , <b>2022</b> , 176, 106064	10.2	0
334	Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0265348	3.7	
333	Achieving virological control in pan-resistant HIV-1 infection: A case series.. <i>EBioMedicine</i> , <b>2022</b> , 77, 103908	10.8	1
332	Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.. <i>New England Journal of Medicine</i> , <b>2022</b> , 386, 1793-1803	59.2	6
331	505. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S354-S355	1	
330	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 50-59	11.6	6
329	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e2323-e2333	11.6	5
328	Role of blood pressure dysregulation on kidney and mortality outcomes in COVID-19. Kidney, blood pressure and mortality in SARS-CoV-2 infection. <i>Journal of Nephrology</i> , <b>2021</b> , 34, 305-314	4.8	3
327	Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. <i>Aids</i> , <b>2021</b> , 35, 1061-1072	3.5	5
326	Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study). <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 1646-1648	5.1	1
325	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology</i> , <b>2021</b> , 3, e253-e261	14.2	75
324	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 675678	8.4	18

323	Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen. <i>Aids</i> , <b>2021</b> , 35, 1513-1516	3.5	2
322	Changes in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Index in Treated HIV-1 Infected People on Virological Suppression Who Switched to a Different Antiretroviral Regimen. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2021</b> , 87, e169-e173	3.1	
321	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab278	1	8
320	Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: A post-hoc analysis of a prospective cohort study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2021</b> , 31, 2156-2164	4.5	6
319	Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. <i>BMC Infectious Diseases</i> , <b>2021</b> , 21, 557	4	0
318	Incidence of deep venous thrombosis in COVID-19 hospitalized patients during the first peak of the Italian outbreak. <i>Phlebology</i> , <b>2021</b> , 36, 375-383	2	10
317	Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database. <i>International Journal of Antimicrobial Agents</i> , <b>2021</b> , 57, 106252	14.3	5
316	Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 451-457	9.5	110
315	Exercise ECG for coronary artery disease screening in people living with HIV. <i>Aids</i> , <b>2021</b> , 35, 933-938	3.5	
314	Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2021</b> , 88, 132-137	3.1	4
313	Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA-matching barrier. <i>Transplant Infectious Disease</i> , <b>2021</b> , 23, e13551	2.7	
312	Pulmonary Vascular Thrombosis in COVID-19 Pneumonia. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , <b>2021</b> , 35, 3631-3641	2.1	16
311	Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection. <i>New Microbiologica</i> , <b>2021</b> , 44, 135-144	1.1	3
310	Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. <i>Scientific Reports</i> , <b>2020</b> , 10, 21291	4.9	16
309	Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 56, 106027	14.3	5
308	In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 2547-2553	5.1	8
307	Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. <i>Clinical Immunology</i> , <b>2020</b> , 217, 108509	9	167
306	Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study). <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 2700-2702	5.1	1

305	Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1232-1243	59.2	56
304	Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2). <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 1332-1337	5.1	5
303	Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment. <i>HIV Medicine</i> , <b>2020</b> , 21, 599-606	2.7	5
302	Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2020</b> , 84, e24-e28	3.1	1
301	HIV-DNA undetectability during chronic HIV infection: frequency and predictive factors. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 2994-2997	5.1	
300	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1277-1285	2.4	164
299	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2020</b> , 83, 240-250	3.1	15
298	Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 55, 105893	14.3	11
297	Infections after Allogeneic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1179-1188	4.7	14
296	Compassionate Use of Remdesivir for Patients with Severe Covid-19. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 2327-2336	59.2	1691
295	COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 6366-6378	15.9	53
294	Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study. <i>PLoS ONE</i> , <b>2020</b> , 15, e0239570	3.7	69
293	548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, S340-S340	1	1
292	Biobanking for COVID-19 research. <i>Panminerva Medica</i> , <b>2020</b> ,	2	21
291	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. <i>PLoS ONE</i> , <b>2020</b> , 15, e0243625	3.7	0
290	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 76, 43-49	3.9	270
289	HIV and tuberculosis: The paradox of dual illnesses and the challenges of their fighting in the history. <i>Tuberculosis</i> , <b>2020</b> , 122, 101921	2.6	9
288	Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 681-689	5.1	2

287	Schistosomiasis, strongyloidiasis and Chagas disease: the leading imported neglected tropical diseases in Italy. <i>Journal of Travel Medicine</i> , <b>2020</b> , 27,	12.9	8
286	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.	5.1	5
285	Stranger Months: How SARS-CoV-2, Fear of Contagion, and Lockdown Measures Impacted Attendance and Clinical Activity During February and March 2020 at an Urban Emergency Department in Milan. <i>Disaster Medicine and Public Health Preparedness</i> , <b>2020</b> , 1-10	2.8	21
284	Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. <i>Viruses</i> , <b>2020</b> , 12,	6.2	5
283	Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance. <i>Aids</i> , <b>2020</b> , 34, 2152-2155	3.5	0
282	Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHT study. <i>Lancet HIV</i> , <b>2020</b> , 7, e740-e751	7.8	29
281	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 1048-1057	27.4	629
280	Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression. <i>Patient</i> , <b>2020</b> , 13, 375-387	3.7	4
279	Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , <b>2020</b> , 22, 91-94	2.8	66
278	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. <i>BMC Public Health</i> , <b>2019</b> , 19, 1291	4.1	3
277	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the IcoNA cohort. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25227	5.4	24
276	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 1363-1367	5.1	17
275	Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2019</b> , 38, 1857-1865	5.3	2
274	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts $\geq 5 \log_{10}$ copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 2732-2741	5.1	5
273	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 1224-1228	3.4	6
272	Pharmacotherapeutic management of HIV in transplant patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 1235-1250	4	2
271	Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 321-331	1.6	3
270	Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 2039-2046	5.1	15

269	LC-MS/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2019</b> , 169, 11-18	3.5	21
268	Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. <i>HIV Medicine</i> , <b>2019</b> , 20 Suppl 1, 3-11	2.7	27
267	Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. <i>HIV Medicine</i> , <b>2019</b> , 20, 264-273	2.7	7
266	Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens. <i>Journal of Medical Virology</i> , <b>2019</b> , 91, 1937-1943	19.7	6
265	Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPPPO" Cohort. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222225	3.7	5
264	Switching antiretrovirals in older patients. <i>Lancet HIV</i> , <b>2019</b> , 6, e640-e641	7.8	
263	A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study. <i>Drug Design, Development and Therapy</i> , <b>2019</b> , 13, 477-479	4.4	2
262	Two-drug regimens with dolutegravir for maintaining viral suppression: looking at the right companion. <i>Aids</i> , <b>2019</b> , 33, 2264-2266	3.5	
261	Brief Report: Outcome of Acute Hepatitis B Virus Infection in HIV-1-Infected Patients: Possible Factors Associated With Resolution or Chronicity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 82, 175-180	3.1	5
260	Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 82, 373-376	3.1	2
259	Rhodococcus defluvi pneumonia: first reported case in humans. <i>Aids</i> , <b>2019</b> , 33, 2261-2263	3.5	3
258	Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. <i>Aids</i> , <b>2019</b> , 33, 1256-1260	3.5	8
257	Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression. <i>Aids</i> , <b>2019</b> , 33, 1987-1994	3.5	1
256	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Name for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , <b>2019</b> , 20, 99-109	2.7	11
255	Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofy324	1	6
254	Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 69-72	1.6	4
253	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 893-903	11.6	75
252	Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. <i>HIV Clinical Trials</i> , <b>2018</b> , 19, 52-60		4

251	Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. <i>HIV Medicine</i> , <b>2018</b> , 19, 324-338	2.7	2
250	Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. <i>HIV Medicine</i> , <b>2018</b> , 19, 252-260	2.7	1
249	Immune activation, inflammation and HIV DNA after 96 weeks of ATV/r monotherapy: a MODAt substudy. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 633-637	1.6	2
248	Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. <i>HIV Medicine</i> , <b>2018</b> , 19, 102-117	2.7	5
247	The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. <i>HIV Medicine</i> , <b>2018</b> , 19, 90-101	2.7	8
246	An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study. <i>Infectious Diseases</i> , <b>2018</b> , 50, 220-222	3.1	3
245	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. <i>BMC Medicine</i> , <b>2018</b> , 16, 79	11.4	16
244	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. <i>BMC Public Health</i> , <b>2018</b> , 18, 870	4.1	13
243	Bictegravir. <i>Current Opinion in HIV and AIDS</i> , <b>2018</b> , 13, 326-333	4.2	16
242	Darunavir for the treatment of HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1149-1163	4	10
241	The association between detected drug resistance mutations and CD4 T-cell decline in HIV-positive individuals maintained on a failing treatment regimen. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 105-116	1.6	1
240	Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?. <i>HIV Medicine</i> , <b>2018</b> , 19, 42-48	2.7	7
239	Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load. <i>PLoS ONE</i> , <b>2018</b> , 13, e0191300	3.7	3
238	Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 177-182	5.1	18
237	Stepping up HIV-1 low-level viraemia surveillance in South Africa. <i>Lancet Infectious Diseases</i> , <b>2018</b> , 18, 130-131	25.5	2
236	Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. <i>Aids</i> , <b>2018</b> , 32, 205-215	3.5	3
235	Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 79, 617-623	3.1	6
234	Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation. <i>Journal of the International AIDS Society</i> , <b>2018</b> , 21, e25200	5.4	3

233	Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. <i>International Journal of Antimicrobial Agents</i> , <b>2018</b> , 52, 492-499	14.3	9
232	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 3460-3470	5.1	7
231	Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1949-1954	5.1	14
230	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , <b>2018</b> , 19, 475	2.7	10
229	Eosinophils from Physiology to Disease: A Comprehensive Review. <i>BioMed Research International</i> , <b>2018</b> , 2018, 9095275	3	95
228	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1955-1964	5.1	20
227	Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 43	4	6
226	Cardiovascular disease in women with HIV-1 infection. <i>International Journal of Cardiology</i> , <b>2017</b> , 241, 50-56	3.2	10
225	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized ATLAS-M trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2055-2059	5.1	20
224	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection—authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 1549-1550 <sup>1</sup>	5.1	1550 <sup>1</sup>
223	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA $\geq 10^4$ copies/mL. <i>Infection</i> , <b>2017</b> , 45, 521-528	5.8	9
222	Antiretroviral therapy in geriatric HIV patients: the GEPO cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2879-2886	5.1	23
221	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , <b>2017</b> , 23, 267.e1-267.e4	9.5	7
220	Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0184128	3.7	8
219	Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186367	3.7	12
218	Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186549	3.7	18
217	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. <i>PLoS ONE</i> , <b>2017</b> , 12, e0177402	3.7	14
216	Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 734	4	2



215	Evolving treatment implementation among HIV-infected pregnant women and their partners: results from a national surveillance study in Italy, 2001-2015. <i>Journal of Global Health</i> , <b>2017</b> , 7, 010407	4.3	2
214	The use of circulating cathodic antigen rapid test and serology for diagnosis of active <i>Schistosoma mansoni</i> infection in migrants in Italy, a non-endemic country: a cross sectional study. <i>Memorias Do Instituto Oswaldo Cruz</i> , <b>2017</b> , 112, 452-455	2.6	6
213	Brief Report: Drop in CD4+ Counts Below 200 Cells/ $\mu$ l After Reaching (or Starting From) Values Higher than 350 Cells/ $\mu$ l in HIV-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 76, 417-422	3.1	1
212	Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. <i>Aids</i> , <b>2017</b> , 31, 835-846	3.5	11
211	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 75, 465-471	3.1	3
210	Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , <b>2017</b> , 18, 171-180	2.7	33
209	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 632-633	5.1	7
208	Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. <i>Annals of Internal Medicine</i> , <b>2017</b> , 166, 9-17	8	30
207	Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. <i>HIV Medicine</i> , <b>2017</b> , 18, 33-44	2.7	10
206	Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 723	4	3
205	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2869-2878	5.1	11
204	Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. <i>PLoS ONE</i> , <b>2017</b> , 12, e0171611	3.7	9
203	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. <i>PLoS ONE</i> , <b>2017</b> , 12, e0173893	3.7	23
202	Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182007	3.7	7
201	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. <i>AIDS Reviews</i> , <b>2017</b> , 19,	1.5	3
200	Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 1163-1171	5.1	56
199	Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 812-815	5.1	6
198	Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. <i>Journal of Infection</i> , <b>2016</b> , 73, 619-623	18.9	10

197	Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3780	1.8	5
196	Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients. <i>Medicine (United States)</i> , <b>2016</b> , 95, e4144	1.8	5
195	High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation Cohort. <i>Medicine (United States)</i> , <b>2016</b> , 95, e4434	1.8	2
194	Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study. <i>Medicine (United States)</i> , <b>2016</b> , 95, e5020	1.8	2
193	Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression. <i>Medicine (United States)</i> , <b>2016</b> , 95, e5222	1.8	4
192	Infection-related and -unrelated malignancies, HIV and the aging population. <i>HIV Medicine</i> , <b>2016</b> , 17, 590-600	2.7	31
191	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 2663-9	5.1	9
190	Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , <b>2016</b> , 17, 471-8	2.7	7
189	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1637-42	5.1	5
188	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1352-60	5.1	3
187	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1056-62	5.1	17
186	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Clinical Microbiology and Infection</i> , <b>2016</b> , 22, 288.e1-8	9.5	27
185	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. <i>PLoS ONE</i> , <b>2016</b> , 11, e0160761	3.7	4
184	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156360	3.7	
183	Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study. <i>Drug Design, Development and Therapy</i> , <b>2016</b> , 10, 1589-603	4.4	5
182	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2016</b> , 71, 263-71	3.1	33
181	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 1245-1253	11.6	15
180	Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. <i>PLoS Medicine</i> , <b>2015</b> , 12, e1001809	11.6	107

179	Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study. <i>HIV Medicine</i> , <b>2015</b> , 16, 533-43	2.7	9
178	Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. <i>Lancet HIV,the</i> , <b>2015</b> , 2, e464-73	7.8	60
177	HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. <i>Clinical Microbiology and Infection</i> , <b>2015</b> , 21, 103.e7-103.e10	9.5	10
176	Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 211, 178-86	7	114
175	Immortal time bias: authorsLreply. <i>Aids</i> , <b>2015</b> , 29, 860-1	3.5	1
174	Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort. <i>HIV Medicine</i> , <b>2015</b> , 16, 412-20	2.7	2
173	Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy. <i>Journal of the International AIDS Society</i> , <b>2015</b> , 18, 20037	5.4	10
172	Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. <i>Aids</i> , <b>2015</b> , 29, 1205-15	3.5	37
171	Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authorsLreply. <i>Aids</i> , <b>2015</b> , 29, 857-9	3.5	
170	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , <b>2015</b> , 10, e0124252	3.7	5
169	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140877	3.7	7
168	Estimating minimum adult HIV prevalence: a cross-sectional study to assess the characteristics of people living with HIV in Italy. <i>AIDS Research and Human Retroviruses</i> , <b>2015</b> , 31, 282-7	1.6	16
167	Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study. <i>Lancet HIV,the</i> , <b>2015</b> , 2, e540-9	7.8	14
166	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. <i>Lancet HIV,the</i> , <b>2015</b> , 2, e98-106	7.8	172
165	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , <b>2015</b> , 20,	19.8	55
164	An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. <i>New Microbiologica</i> , <b>2015</b> , 38, 443-90	1.1	6
163	Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. <i>BMC Infectious Diseases</i> , <b>2014</b> , 14, 79	4	19
162	Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 58, 1312-21	11.6	107

161	Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 1436-9	5.1	4
160	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 735-41	5.1	15
159	A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. <i>Infection</i> , <b>2014</b> , 42, 757-62	5.8	4
158	Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. <i>BMC Nephrology</i> , <b>2014</b> , 15, 51	2.7	6
157	Optimal dietary calcium intake in HIV treated patients: no femoral osteoporosis but higher cardiovascular risk. <i>Clinical Nutrition</i> , <b>2014</b> , 33, 363-6	5.9	4
156	Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. <i>Antiviral Research</i> , <b>2014</b> , 108, 44-7	10.8	6
155	Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19806	5.4	4
154	Predictors of lack of serological response to syphilis treatment in HIV-infected subjects. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19654	5.4	1
153	An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19771	5.4	1
152	Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19811	5.4	1
151	Dolutegravir: a new option for HIV treatment. <i>Future Virology</i> , <b>2014</b> , 9, 801-810	2.4	0
150	Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies. <i>PLoS Medicine</i> , <b>2014</b> , 11, e1001718	11.6	89
149	Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 210, 354-62	7	232
148	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 3085-94	5.1	6
147	Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent. <i>AIDS Research and Human Retroviruses</i> , <b>2014</b> , 30, 1243-50	1.6	4
146	Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. <i>Aids</i> , <b>2014</b> , 28, 2407-15	3.5	15
145	Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2014</b> , 67, 258-67	3.1	2
144	Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results. <i>Aids</i> , <b>2014</b> , 28, 2269-79	3.5	19

143	Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals. <i>Aids</i> , <b>2014</b> , 28, 1351-6	3.5	27
142	Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord. <i>Aids</i> , <b>2014</b> , 28, 2297-306	3.5	33
141	Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. <i>Therapeutics and Clinical Risk Management</i> , <b>2014</b> , 10, 9-15	2.9	10
140	Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. <i>PLoS ONE</i> , <b>2014</b> , 9, e87160	3.7	28
139	Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness. <i>New Microbiologica</i> , <b>2014</b> , 37, 285-306	1.1	
138	Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up. <i>Clinical Microbiology and Infection</i> , <b>2013</b> , 19, E542-4	9.5	18
137	Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy. <i>HIV Medicine</i> , <b>2013</b> , 14, 153-60	2.7	19
136	Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease. <i>Aids</i> , <b>2013</b> , 27, 2335-44	3.5	14
135	Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 2960-3	5.1	4
134	Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , <b>2013</b> , 10, e1001510	11.6	212
133	Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 207, 759-67	7	6
132	The incidence of AIDS-defining illnesses at a current CD4 count $\geq 200$ cells/ $\mu$ l in the post-combination antiretroviral therapy era. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 1038-47	11.6	79
131	Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 1800-9	11.6	26
130	Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs. <i>Liver International</i> , <b>2013</b> , 33, 1113-20	7.9	10
129	Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. <i>Cancer</i> , <b>2013</b> , 119, 2710-9	6.4	2
128	In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 2525-32	5.1	27
127	Inconsistent condom use among HIV-positive women in the "Treatment as Prevention Era": data from the Italian DIDI study. <i>Journal of the International AIDS Society</i> , <b>2013</b> , 16, 18591	5.4	16
126	Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine. <i>Aids</i> , <b>2013</b> , 27, 2661-3	3.5	

125	B-cell subset alterations and correlated factors in HIV-1 infection. <i>Aids</i> , <b>2013</b> , 27, 1209-17	3.5	56
124	Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 339-45	3.1	11
123	Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , <b>2013</b> , 13, 471	4	58
122	Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfecting patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e64283	3.7	17
121	Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis. <i>BMC Health Services Research</i> , <b>2012</b> , 12, 38	2.9	
120	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases</i> , <b>2012</b> , 12, 119-27	25.5	33
119	Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. <i>European Journal of Epidemiology</i> , <b>2012</b> , 27, 657-65	12.1	56
118	Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. <i>PLoS ONE</i> , <b>2012</b> , 7, e41673	3.7	24
117	Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. <i>International Journal of Cancer</i> , <b>2012</b> , 130, 2990-6	7.5	24
116	Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 447-58	1.6	9
115	The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*. <i>HIV Medicine</i> , <b>2012</b> , 13, 62-72	2.7	19
114	CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. <i>PLoS Medicine</i> , <b>2012</b> , 9, e1001194	11.6	119
113	Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 853-61	11.6	23
112	All-cause mortality in treated HIV-infected adults with CD4 $\leq 500$ /mm <sup>3</sup> compared with the general population: evidence from a large European observational cohort collaboration. <i>International Journal of Epidemiology</i> , <b>2012</b> , 41, 433-45	7.8	184
111	Immune recovery and T cell subset analysis during effective treatment with maraviroc. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 2474-8	5.1	9
110	Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 1224-7	5.1	14
109	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 2541-2542	5.1	
108	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 213-7	5.1	26

107	Monotherapy with atazanavir as a simplification strategy: results from an observational study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 60, e101-3	3.1	4
106	Polyclonal serum-free light chains elevation in HIV-infected patients. <i>Aids</i> , <b>2012</b> , 26, 2107-10	3.5	8
105	Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens. <i>Aids</i> , <b>2012</b> , 26, 1837-40	3.5	11
104	Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. <i>Aids</i> , <b>2012</b> , 26, 1917-26	3.5	56
103	Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 59, 294-9	3.1	12
102	HIV protease inhibitors: present and future. <i>Future Virology</i> , <b>2011</b> , 6, 571-580	2.4	
101	Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 56, e113-5	3.1	18
100	Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. <i>Aids</i> , <b>2011</b> , 25, 2249-58	3.5	50
99	Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 56, e34-5	3.1	1
98	Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. <i>Aids</i> , <b>2011</b> , 25, 1385-94	3.5	139
97	Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 1103-12	1.6	38
96	Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. <i>HIV Medicine</i> , <b>2011</b> , 12, 4-13	2.7	26
95	Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients. <i>HIV Medicine</i> , <b>2011</b> , 12, 109-17	2.7	15
94	Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. <i>Clinical Microbiology and Infection</i> , <b>2011</b> , 17, 928-34	9.5	18
93	Longitudinal evaluation of occult hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption. <i>Infection</i> , <b>2011</b> , 39, 121-6	5.8	12
92	Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. <i>BMC Infectious Diseases</i> , <b>2011</b> , 11, 23	4	4
91	No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 391-8	19.7	1
90	Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 2372-8	5.1	28

89	Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 1932-4	5.1	7
88	Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 1811-5	7	87
87	Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 56, e51-4	3.1	12
86	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , <b>2010</b> , 20, 759-65	1.9	38
85	Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 425-33	5.1	48
84	Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 1316-21	11.6	53
83	HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme. <i>International Journal of STD and AIDS</i> , <b>2010</b> , 21, 224-5	1.4	6
82	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial. <i>Journal of Clinical Virology</i> , <b>2010</b> , 47, 253-7	4.5	4
81	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , <b>2010</b> , 376, 340-5	4 <sup>0</sup>	77
80	Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. <i>Aids</i> , <b>2010</b> , 24, 924-8	3.5	38
79	Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. <i>Archives of Internal Medicine</i> , <b>2010</b> , 170, 410-9		35
78	Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. <i>Antiviral Therapy</i> , <b>2010</b> , 15, 165-75	1.6	14
77	Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients. <i>HIV Medicine</i> , <b>2010</b> , 11, 104-13	2.7	73
76	Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 64, 1341-4	5.1	3
75	Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2009</b> , 51, 179-84	3.1	4
74	Common genetic variation and the control of HIV-1 in humans. <i>PLoS Genetics</i> , <b>2009</b> , 5, e1000791	6	310
73	Risk of developing specific AIDS-defining illnesses in patients coinfecting with HIV and hepatitis C virus with or without liver cirrhosis. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 612-22	11.6	47
72	Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy. <i>Infection</i> , <b>2009</b> , 37, 270-82	5.8	7



71	Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. <i>Aids</i> , <b>2009</b> , 23, 455-60	3.5	63
70	Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2009</b> , 50, 192-5	3.1	7
69	Magnitude and determinants of CD4 recovery after HAART resumption after 1 cycle of treatment interruption. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2009</b> , 52, 588-94	3.1	6
68	Raltegravir in treatment naive patients. <i>European Journal of Medical Research</i> , <b>2009</b> , 14 Suppl 3, 22-9	4.8	5
67	In Vivo Treatment with Fusion Inhibitor Enfuvirtide Leads to Increased IL-12 Production by Autologous in Vitro Activated Monocytes from HIV-infected Individuals. <i>Journal of Antivirals &amp; Antiretrovirals</i> , <b>2009</b> , 01, 043-050	2	
66	Etravirine for the treatment of HIV infection. <i>Expert Review of Anti-Infective Therapy</i> , <b>2008</b> , 6, 427-33	5.5	29
65	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. <i>Aids</i> , <b>2008</b> , 22, 2143-53	3.5	180
64	Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 62, 384-7	5.1	6
63	HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. <i>Journal of Medical Virology</i> , <b>2008</b> , 80, 201-8	19.7	13
62	Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations. <i>Journal of Medical Virology</i> , <b>2008</b> , 80, 937-41	19.7	9
61	Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2007</b> , 101, 339-44	3.1	9
60	First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006). <i>Infection</i> , <b>2007</b> , 35, 134-42	5.8	12
59	Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. <i>Infection</i> , <b>2007</b> , 35, 451-6	5.8	3
58	Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. <i>European Journal of Endocrinology</i> , <b>2007</b> , 156, 503-9	6.5	33
57	Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion. <i>Journal of Leukocyte Biology</i> , <b>2007</b> , 82, 1212-20	6.5	14
56	Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2007</b> , 60, 831-6	5.1	15
55	Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. <i>Aids</i> , <b>2007</b> , 21, 1648-51	3.5	16
54	Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity. <i>Aids</i> , <b>2007</b> , 21, 2366-7	3.5	0

53	A whole-genome association study of major determinants for host control of HIV-1. <i>Science</i> , <b>2007</b> , 317, 944-7	33.3	999
52	Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir. <i>Journal of Medical Virology</i> , <b>2006</b> , 78, 1537-41	19.7	9
51	Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). <i>Journal of Antimicrobial Chemotherapy</i> , <b>2006</b> , 57, 1055-64	5.1	5
50	Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. <i>Archives of Internal Medicine</i> , <b>2006</b> , 166, 1632-41		869
49	Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). <i>Aids</i> , <b>2006</b> , 20, 795-803	3.5	117
48	The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2006</b> , 41, 447-52	3.1	7
47	Immunological basis for IgE hyper-production in enfuvirtide-treated HIV- positive patients. <i>Journal of Clinical Immunology</i> , <b>2006</b> , 26, 168-76	5.7	4
46	The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development. <i>Drugs</i> , <b>2005</b> , 65, 879-904	12.1	48
45	Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. <i>HIV Medicine</i> , <b>2005</b> , 6, 145-50	2.7	48
44	Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 61, 545-9	2.8	12
43	Cross-sectional and retrospective questionnaire-trial to evaluate exercise habits in a sample of HIV-infected individuals with type 2 diabetes mellitus. <i>Sport Sciences for Health</i> , <b>2005</b> , 1, 81-90	1.3	1
42	Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2005</b> , 56, 790-2	5.1	20
41	Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen. <i>AIDS Research and Human Retroviruses</i> , <b>2005</b> , 21, 545-54	1.6	4
40	A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial. <i>Antiviral Therapy</i> , <b>2005</b> , 10, 735-743	1.6	30
39	Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2004</b> , 48, 3253-9	5.9	74
38	Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients. <i>Aids</i> , <b>2004</b> , 18, 2205-8	3.5	5
37	Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection. <i>Aids</i> , <b>2004</b> , 18, 121-3	3.5	9
36	Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. <i>HIV Medicine</i> , <b>2004</b> , 5, 334-43	2.7	43

35	Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. <i>HIV Medicine</i> , <b>2004</b> , 5, 437-47	2.7	46
34	Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. <i>Journal of Medical Virology</i> , <b>2004</b> , 72, 181-6	19.7	7
33	Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 39, 1681-91	11.6	111
32	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , <b>2004</b> , 364, 51-62	4.0	267
31	Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome. <i>Aids</i> , <b>2004</b> , 18, 821-3	3.5	2
30	The NIQ of Lopinavir is Predictive of a 48-Week Virological Response in Highly Treatment-Experienced HIV-1-Infected Subjects Treated with a Lopinavir/Ritonavir-Containing Regimen. <i>Antiviral Therapy</i> , <b>2004</b> , 9, 537-543	1.6	10
29	Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients. <i>Aids</i> , <b>2003</b> , 17, 2669-71	3.5	11
28	Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. <i>Aids</i> , <b>2003</b> , 17, 1993-5	3.5	40
27	Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure. <i>AIDS Research and Human Retroviruses</i> , <b>2003</b> , 19, 1151-3	1.6	15
26	Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 188, 1827-33	7	28
25	Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 188, 635-42	7	108
24	Long-term response in patients receiving HAART including nelfinavir: experience from two Italian centers. <i>Journal of Chemotherapy</i> , <b>2002</b> , 14, 189-93	2.3	
23	Reversal of CSF positivity for JC virus genome by cidofovir in a patient with systemic lupus erythematosus and progressive multifocal leukoencephalopathy. <i>Neurological Sciences</i> , <b>2001</b> , 22, 17-20	3.5	26
22	Relation between CD4 cell counts and HIV RNA levels at onset of opportunistic infections. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2001</b> , 27, 44-8	3.1	9
21	Relation Between CD4 Cell Counts and HIV RNA Levels at Onset of Opportunistic Infections. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2001</b> , 27, 44-48	3.1	8
20	Role of brain biopsy in the management of focal brain lesions in HIV-infected patients. Gruppo Italiano Cooperativo AIDS & Tumori. <i>Neurology</i> , <b>2000</b> , 54, 993-7	6.5	36
19	Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy. <i>Journal of Neurology</i> , <b>1999</b> , 246, 723-5	5.5	33
18	Use of polymerase chain reaction assays of aqueous humor in the differential diagnosis of retinitis in patients infected with human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , <b>1997</b> , 24, 1100-6	11.6	35

17	A comparison of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients. <i>Journal of Neurology</i> , <b>1997</b> , 244, 35-9	5.5	37
16	Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. <i>Aids</i> , <b>1996</b> , 10, 951-8	3.5	140
15	Thallium-201 single photon emission computed tomography in the management of contrast-enhancing brain lesions in a patient with AIDS. <i>Clinical Infectious Diseases</i> , <b>1996</b> , 23, 185-6	11.6	5
14	Ganciclovir therapy for cytomegalovirus (CMV) infection of the central nervous system in AIDS patients: monitoring by CMV DNA detection in cerebrospinal fluid. <i>Journal of Infectious Diseases</i> , <b>1995</b> , 171, 1603-6	7	39
13	Cerebrospinal fluid S-adenosylmethionine (SAME) and glutathione concentrations in HIV infection: effect of parenteral treatment with SAME. <i>Neurology</i> , <b>1995</b> , 45, 1678-83	6.5	80
12	Diagnosis of virus-associated opportunistic diseases of the central nervous system in patients with HIV infection by polymerase chain reaction on cerebrospinal fluid. <i>Annals of the New York Academy of Sciences</i> , <b>1994</b> , 724, 170-2	6.5	3
11	Polymerase chain reaction for <i>Toxoplasma gondii</i> DNA in the cerebrospinal fluid of AIDS patients with focal brain lesions. <i>Aids</i> , <b>1994</b> , 8, 1691-4	3.5	38
10	Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. <i>Lancet, The</i> , <b>1993</b> , 342, 398-401	40	277
9	T and B cell responses to cytomegalovirus antigens in healthy blood donors and bone marrow transplant recipients. <i>FEMS Immunology and Medical Microbiology</i> , <b>1993</b> , 7, 55-62		5
8	Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. <i>Journal of Infectious Diseases</i> , <b>1992</b> , 166, 1408-11	7	113
7	Mediator release in cerebrospinal fluid of human immunodeficiency virus-positive patients with central nervous system involvement. <i>Journal of Neuroimmunology</i> , <b>1992</b> , 38, 155-61	3.5	16
6	Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement. <i>Annals of Neurology</i> , <b>1991</b> , 29, 21-5	9.4	131
5	Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy. <i>Lancet, The</i> , <b>1991</b> , 337, 1488	40	7
4	Kappa light chain predominance in serum and cerebrospinal fluid from human immunodeficiency virus type 1 (HIV-1)-infected patients. <i>Journal of Neuroimmunology</i> , <b>1991</b> , 32, 259-68	3.5	7
3	Clinical and immunological aspects of HIV infection in drug addicts. <i>Clinical Immunology and Immunopathology</i> , <b>1989</b> , 50, S166-76		17
2	Oligoclonal IgG bands in cerebrospinal fluid and serum during asymptomatic human immunodeficiency virus infection. <i>Annals of Neurology</i> , <b>1988</b> , 24, 277-9	9.4	15
1	Viral antibodies in serum and cryoprecipitate of patients with essential mixed and secondary cryoglobulinemia. Preliminary results. <i>Research in Clinic and Laboratory</i> , <b>1986</b> , 16, 345-8		2